IRF3 and ovarian carcinoma: In contrast to T80 and HMEC cells, we did not observe increases in PLSCR1 expression (or p-IRF3) in ovarian cancer cell lines, despite similar transfection efficiencies between T80 and the ovarian cancer cell lines (HEY, TOV21G, and TOV112D).